Vion Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference

NEW HAVEN, Conn., Sept. 9 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. today announced that it would make a corporate presentation at the 11th Annual Rodman & Renshaw Healthcare Conference in New York City.

Slides from the presentation will be available on the Company's website, www.vionpharm.com, at the time of the presentation.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM) (laromustine) Injection and Triapine(R). The Company has submitted a New Drug Application to the FDA for Onrigin(TM) for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. The FDA's Oncologic Drug Advisory Committee has recommended to the FDA that a new randomized trial for Onrigin be completed prior to regulatory approval. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

SOURCE Vion Pharmaceuticals, Inc.

CONTACT: Alan Kessman, Chief Executive Officer, Howard B. Johnson,
President & CFO, +1-203-498-4210

Web site: http://www.vionpharm.com/